Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from a Phase 2 study evaluating the safety, efficacy and therapeutic dose range of MK-7264 (formerly AF-219) for the treatment of chronic cough. The highest dose evaluated, 50 mg, reduced Awake Cough Frequency (coughs/hour), the primary endpoint, by 37 percent from baseline relative to placebo (p=0.003). The 50 mg dose also demonstrated a reduction in patient-reported cough severity.Language: EnglishContact: Merc...
Source: Merck.com - Research and Development News - May 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK chronic cough MSD NYSE:MRK Source Type: news

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City: KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) fromC-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/grazoprevir3...
Source: Merck.com - Research and Development News - April 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news

Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company ’s established and investigational infectious disease medicines at this year’s 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25 in Vienna, Austria.Language: EnglishContact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-295-0928orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740...
Source: Merck.com - Research and Development News - April 19, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ECCMID MSD NYSE:MRK Source Type: news

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Dateline City: KENILWORTH, N.J.& NEW YORK Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or MetforminKENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.Language: EnglishContact: Merck Media:Doris Li, (908) 246-5701orMerck Investor:Amy Klug, (908) 740-1898orKristen Drake, (908) 236-4223orPfizer Media:Steve Danehy, (212) 733-1538orPfizer Investor:Ryan Crowe, (212) 733-8160Ticker Slug:Ticker:MRKExchange:NYSET...
Source: Merck.com - Research and Development News - March 6, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK #Pfizer $MRK $PFE Januvia MSD NYSE:MRK Source Type: news

Merck ’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
Dateline City: KENILWORTH, N.J. Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopo...
Source: Merck.com - Research and Development News - February 26, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news

In First Phase 3 Trial, Merck ’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company ’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSkip Irvine, 267-305-0338orInvestors:Amy Klug, 908-740-1898orMichael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more (Source: Merck.c...
Source: Merck.com - Research and Development News - February 24, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer ’s Disease to Stop for Lack of Efficacy
Dateline City: KENILWORTH, N.J. APECS Study in People with Prodromal Alzheimer ’s Disease to ContinueKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer ’s disease (AD).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Ian McConnell, 908-...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Merck ’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Dateline City: KENILWORTH, N.J. Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na ïve Adults after 48 weeks of TreatmentKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Carmen de Gourville, 267-664-0146orInvestors:Teri Loxam, 908-740-198...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Doravirine HIV MSD NYSE:MRK Source Type: news

Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
Dateline City: KENILWORTH, N.J. Results of First Phase 3 Trial Anticipated in Late 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer ’s disease (AD).Language: EnglishContact: MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740-1921orInvestors:...
Source: Merck.com - Research and Development News - November 2, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK alzheimers NYSE:MRK verubecestat Source Type: news

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language: Englishread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 15, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Provides Update on Odanacatib Development Program
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck ’s investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Teri Loxam, 908-740-1986Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 2, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK odanacatib Source Type: news

Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
Dateline City: KENILWORTH, N.J. Marketing Authorization Application to the European Medicines Agency Currently Under ReviewKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis.Language: EnglishContact: MerckMe...
Source: Merck.com - Research and Development News - August 5, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Glargine MSD Source Type: news

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS ® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
Dateline City: KENILWORTH, N.J. Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company ’s investigational once-daily formulation of ISENTRESS ® (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from...
Source: Merck.com - Research and Development News - July 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK HIV ISENTRESS MSD NYSE:MRK Source Type: news

Results of Phase 2 Study of Merck ’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company ’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. Language: English Contact: Merck Media: Pamela Eisele, (267) 305-3558 or Robert ...
Source: Merck.com - Research and Development News - June 20, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news

Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. Language: English ...
Source: Merck.com - Research and Development News - June 20, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news

Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Dateline City: KENILWORTH, N.J. KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA® (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. Language: ...
Source: Merck.com - Research and Development News - June 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Merck ’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck ’s investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English Contact: Merck Media: Doris Li, 908-246-5701 Kristen...
Source: Merck.com - Research and Development News - June 13, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news

Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English ...
Source: Merck.com - Research and Development News - June 13, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news

Updated Findings from KEYNOTE-012 for KEYTRUDA ® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52 nd An...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

KEYTRUDA ® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be pr...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). ...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodg...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

New Data from Phase 2 Study Evaluating KEYTRUDA ® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with advanced cancers characterized as deficient for DNA mismatch repair (MMR). Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558 Kim Hamilton, 908-740-1863 or Investors: Teri Loxam, 908-740-1986 Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE ...
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced cancers characterized as deficient for DNA mismatch repair (MMR). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740...
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

New Data for KEYTRUDA ® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in combination with other treatment regimens including talimogene laherparepvec, dabrafenib plus trametinib, or low-dose ipilimumab in patients with advanced melanoma. Language: English Contact: Merck Media Contacts: Pamela Eisele, 267-305-3558 or An Phan, 908-255-6325 or Investor Conta...
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with other treatment regimens including talimogene laherparepvec, dabrafenib plus trametinib, or low-dose ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eis...
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

New Data Evaluating KEYTRUDA ® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed over...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news

New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 ...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreate...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA® ...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate  Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new fi...
Source: Merck.com - Research and Development News - May 18, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall s...
Source: Merck.com - Research and Development News - May 18, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

New KEYTRUDA ® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 – 7, 2016. Language:...
Source: Merck.com - Research and Development News - May 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chica...
Source: Merck.com - Research and Development News - May 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

Merck to Present New Data for KEYTRUDA ® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this year’s American Association for Cancer Research (AACR) Annual Meeting in New Or...
Source: Merck.com - Research and Development News - April 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK AACR Keytruda NYSE:MRK Source Type: news

Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this year’s American Association for Cancer ...
Source: Merck.com - Research and Development News - April 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK AACR Keytruda NYSE:MRK Source Type: news

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
Dateline City: KENILWORTH, N.J. Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress™...
Source: Merck.com - Research and Development News - March 30, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Merck MRK NYSE:MRK ZEPATIER Source Type: news

Merck ’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
Dateline City: KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the company ’s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS ® (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. Language: English Contact: ...
Source: Merck.com - Research and Development News - February 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ISENTRESS NYSE:MRK Source Type: news

Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
Dateline City: KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the company’s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS® (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. ...
Source: Merck.com - Research and Development News - February 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ISENTRESS NYSE:MRK Source Type: news

Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease
Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimer’s Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the company’s investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimer’s disease (AD)...
Source: Merck.com - Research and Development News - January 28, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the company’s marketing authorization application (MAA) for elbasvir/grazoprevir (50mg/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. Language: English Contact: MerckMed...
Source: Merck.com - Research and Development News - December 18, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK elbasvir grazoprevir NYSE:MRK Source Type: news

Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
Dateline City: KENILWORTH, N.J. New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, across a r...
Source: Merck.com - Research and Development News - December 8, 2015 Category: Pharmaceuticals Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK ASH cancer Keytruda NYSE:MRK Source Type: news

Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone
Dateline City: KENILWORTH, N.J. Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lenalidomide and Dexamethasone KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today new study findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with lenalidomide and low-dose dexamethaso...
Source: Merck.com - Research and Development News - December 7, 2015 Category: Pharmaceuticals Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK ASH Keytruda NYSE:MRK Source Type: news

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) and Merck’s KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-l...
Source: Merck.com - Research and Development News - November 19, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting®
Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the company’s C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens – a regimen of grazoprevir1, MK-36822 and elbasvir3; and a regimen of grazoprevir, MK-3...
Source: Merck.com - Research and Development News - November 16, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD The Liver Meeting Source Type: news

Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting®
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patien...
Source: Merck.com - Research and Development News - November 15, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news

Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting® Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company’s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotyp...
Source: Merck.com - Research and Development News - November 15, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news

Merck Provides Update on REVEAL Outcomes Study
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data. Language: ...
Source: Merck.com - Research and Development News - November 13, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News anacetrapib Merck MRK MSD NYSE:MRK REVEAL Source Type: news

Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational...
Source: Merck.com - Research and Development News - November 5, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
Dateline City: KENILWORTH, N.J. New Data Will Also be Presented from Phase 2a C-CREST Trials of Merck’s Investigational Triple-Combination Chronic Hepatitis C Therapies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical trials of its investigational treatment portfolio for chronic hepatitis C virus (HCV) are scheduled to be presented at The Liver Meeting® 2015 (the 66th annual scientific congress of the American Association fo...
Source: Merck.com - Research and Development News - October 20, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news